Compare BIIB & ULTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIIB | ULTA |
|---|---|---|
| Founded | 1978 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 23.8B |
| IPO Year | 1991 | 2007 |
| Metric | BIIB | ULTA |
|---|---|---|
| Price | $173.85 | $594.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 26 |
| Target Price | $177.40 | ★ $578.17 |
| AVG Volume (30 Days) | ★ 2.0M | 878.1K |
| Earning Date | 10-30-2025 | 12-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 4.50 |
| EPS | 10.97 | ★ 26.17 |
| Revenue | $10,065,900,000.00 | ★ $11,982,078,000.00 |
| Revenue This Year | $3.61 | $9.76 |
| Revenue Next Year | N/A | $4.13 |
| P/E Ratio | ★ $15.86 | $22.99 |
| Revenue Growth | 4.77 | ★ 5.45 |
| 52 Week Low | $110.04 | $309.01 |
| 52 Week High | $185.17 | $611.90 |
| Indicator | BIIB | ULTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.20 | 63.77 |
| Support Level | $169.24 | $585.32 |
| Resistance Level | $180.79 | $606.99 |
| Average True Range (ATR) | 4.98 | 19.13 |
| MACD | -1.64 | 5.84 |
| Stochastic Oscillator | 35.73 | 80.66 |
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Ulta Beauty is the largest specialized beauty retailer in the US with about 1,500 freestanding stores. The firm offers cosmetics (39% of 2024 sales), fragrances (13%), skin care (23%), and hair care products (19%). It also has salon services, including hair, makeup, skin, and brow, that account for about 4% of its revenue and drive traffic. Outside of the US, Ulta acquired premium beauty retailer Space NK and its 83 stores in the UK and Ireland in 2025, is opening franchised stores in Mexico, and has formed a joint venture to expand into the Middle East. In addition, Ulta collects royalties through its Target partnership (set to end in 2026) and credit card revenue. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.